Pfizer-BioNTech Vaccine Hits 90% Effectiveness in Covid Fight
In a breakthrough, the coronavirus vaccine developed by US giant Pfizer and German biotech firm BioNTech is proving to be a game-changer. Early results reveal it is 90% effective at preventing Covid-19 infection.
Leading the Global Race
The Pfizer-BioNTech jab is one of a dozen vaccines in the world’s final testing phase. But it’s the first to deliver solid results, putting it ahead in the fight against the pandemic.
Massive Supply Plans Announced
The companies aim to deliver 50 million doses by the end of 2020, with a staggering 1.3 billion expected by the close of 2021. This could revolutionise vaccine availability worldwide.
Phase 3 Trials Show Promise
- 43,538 volunteers from six countries took part
- Participants received two doses—vaccine or placebo
- Analysis showed 90% protection within 28 days of vaccination
Such encouraging data could pave the way for mass immunisation and a step towards beating the pandemic once and for all.
